Breakpoint cluster region-Abelson gene (BCR-ABL) tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of patients with chronic myeloid leukemia (CML). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.